Sana Biotechnology (SANA)
(Delayed Data from NSDQ)
$5.04 USD
-0.37 (-6.84%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $5.04 0.00 (0.00%) 5:18 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.04 USD
-0.37 (-6.84%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $5.04 0.00 (0.00%) 5:18 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Zacks News
4 Stocks to Keep a Tab on for Amazing Earnings Acceleration
by Tirthankar Chakraborty
Notable companies to have witnessed solid earnings acceleration as of now are Sana Biotechnology (SANA), LifeMD (LFMD), Evolus (EOLS) and Expro Group Holdings (XPRO).
Are You Looking for a Top Momentum Pick? Why Sana Biotechnology (SANA) is a Great Choice
by Zacks Equity Research
Does Sana Biotechnology (SANA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why
by Zacks Equity Research
Sana Bio (SANA) rallies 105% after the company reports encouraging pipeline progress with its candidates, SC291 and SC262, for oncology and autoimmune indications.
Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for CSML
Can Cigna's (CI) Q1 Earnings Beat on Medical Customers Growth?
by Zacks Equity Research
The first-quarter results of Cigna (CI) are likely to reflect an expanding customer base and growth in specialty pharmacy services.
Wall Street Analysts Believe Sana (SANA) Could Rally 83.17%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 83.2% in Sana (SANA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does Sana (SANA) Have the Potential to Rally 78.23% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 78.2% in Sana (SANA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.